Can biologic nanoparticles initiate nephrolithiasis?
Lieske
John C
JC
Mayo Clinic, Division of Nephrology and Hypertension, 200 1st Street SW, Stabile 7-03, Rochester, MN 55905, USA. lieske.john@mayo.edu
D000818:Animals; D015331:Cohort Studies; D004195:Disease Models, Animal; D005069:Evaluation Studies as Topic; D006801:Humans; D015994:Incidence; D053758:Nanoparticles / Q000009:adverse effects*; D053040:Nephrolithiasis / Q000453:epidemiology* / Q000209:etiology* / Q000503:physiopathology; D018570:Risk Assessment; D012680:Sensitivity and Specificity